Premium
A novel prognostic model for tongue squamous cell carcinoma based on the characteristics of tumour and its microenvironment: iBD score
Author(s) -
Yu Pei,
Wang Weiwang,
Zhuang Zehang,
Xie Nan,
Xu Jieyun,
Wang Cheng,
Hou Jingsong,
Han Xiaozhe,
Liu Xiqiang
Publication year - 2019
Publication title -
histopathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.626
H-Index - 124
eISSN - 1365-2559
pISSN - 0309-0167
DOI - 10.1111/his.13790
Subject(s) - medicine , pathological , stage (stratigraphy) , lymph node , oncology , tumor budding , tongue , t stage , metastasis , basal cell , lymph node metastasis , pathology , overall survival , cancer , biology , paleontology
Aims Tumour budding and invasive depth can predict survival of patients with tongue squamous cell carcinoma ( TSCC ), while the prognostic value of tumour microenvironment ( TME ) remains unknown. Here, both characteristics of the tumour and its microenvironment were examined and a novel prognostic model has been proposed. Methods and results A total of 246 patients with TSCC were included. Using H&E‐stained sections, pathological parameters of tumour and the TME were assessed. Inflammatory response (i), tumour budding (B) and invasive depth (D) were combined as iBD score. The association between these variables and the patient survival was determined. Both tumour budding and inflammatory status were independent variables for predicting overall survival ( OS ) and disease‐free survival ( DFS ) of TSCC patients. Invasive depth was correlated with differentiation, T classification, lymph node metastasis, clinical stage and recurrence ( P < 0.05). The novel iBD model was strongly correlated with T classification, lymph node metastasis, clinical stage and recurrence, and showed clear distinction of scores 0, 1 and 2. High iBD score had a strong association with reduced OS and DFS ( P < 0.01). Conclusions The iBD scoring model is strongly associated with lymph node metastasis and recurrence in TSCC and could be a promising survival predictor for TSCC patients.